The original version of this article unfortunately contained a mistake in the Discussion section. The line that currently reads "During this 4-week period while off PCSK9 monoclonal antibody therapy, the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/ or other lipid-altering drugs." should be changed to "During this 4-week stabilization period (while off PCSK9 monoclonal antibody therapy for at least 8 weeks), the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/or other lipid-altering drugs."
G. Kees Hovingh 5
Published online: 27 April 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018
Correction to: Cardiovasc Drugs Ther https://doi.org/10.1007/s10557-018-6784-z
The original version of this article unfortunately contained a mistake in the Discussion section. The line that currently reads "During this 4-week period while off PCSK9 monoclonal antibody therapy, the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/ or other lipid-altering drugs." should be changed to "During this 4-week stabilization period (while off PCSK9 monoclonal antibody therapy for at least 8 weeks), the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/or other lipid-altering drugs."
The online version of the original article can be found at https://doi.org/ 10.1007/s10557-018-6784-z * Harold E. Bays hbaysmd@outlook.com
